Acorda Therapeutics Inc. (NASDAQ:ACOR)’s share price fell 1.2% during mid-day trading on Monday . The stock traded as low as $25.44 and last traded at $25.90, with a volume of 281,727 shares changing hands. The stock had previously closed at $26.21.

Several research firms have recently issued reports on ACOR. Zacks Investment Research downgraded shares of Acorda Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 28th. Aegis upped their price objective on shares of Acorda Therapeutics from $40.00 to $52.00 and gave the company a “buy” rating in a report on Wednesday, June 1st. Leerink Swann restated a “hold” rating and set a $29.00 price objective (down previously from $31.00) on shares of Acorda Therapeutics in a report on Sunday, May 22nd. Cowen and Company restated an “outperform” rating and set a $60.00 price objective (down previously from $65.00) on shares of Acorda Therapeutics in a report on Friday, May 20th. Finally, Evercore ISI restated a “hold” rating and set a $32.00 price objective on shares of Acorda Therapeutics in a report on Friday, May 20th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $38.67.

The company has a market cap of $1.13 billion and a price-to-earnings ratio of 81.72. The company has a 50 day moving average of $26.54 and a 200-day moving average of $30.86.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by $0.01. The firm earned $115.90 million during the quarter, compared to analyst estimates of $115.36 million. The business’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.15 EPS. Equities research analysts forecast that Acorda Therapeutics Inc. will post $0.74 earnings per share for the current year.

In other news, Director Lorin Randall sold 1,488 shares of Acorda Therapeutics stock in a transaction dated Tuesday, April 19th. The stock was sold at an average price of $28.68, for a total value of $42,675.84. Following the completion of the transaction, the director now owns 1,488 shares in the company, valued at approximately $42,675.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Andrew A. Hindman sold 4,860 shares of Acorda Therapeutics stock in a transaction dated Friday, May 13th. The shares were sold at an average price of $26.11, for a total value of $126,894.60. Following the completion of the transaction, the insider now owns 49,670 shares of the company’s stock, valued at approximately $1,296,883.70. The disclosure for this sale can be found here.

Several large investors have modified their holdings of ACOR. State Board of Administration of Florida Retirement System raised its stake in shares of Acorda Therapeutics by 36.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 61,387 shares of the biopharmaceutical company’s stock valued at $2,626,000 after buying an additional 16,478 shares during the period. Nationwide Fund Advisors raised its stake in shares of Acorda Therapeutics by 1.5% in the fourth quarter. Nationwide Fund Advisors now owns 39,019 shares of the biopharmaceutical company’s stock valued at $1,669,000 after buying an additional 566 shares during the period. Rhumbline Advisers raised its stake in shares of Acorda Therapeutics by 6.0% in the fourth quarter. Rhumbline Advisers now owns 55,690 shares of the biopharmaceutical company’s stock valued at $2,382,000 after buying an additional 3,150 shares during the period. ProShare Advisors LLC raised its stake in shares of Acorda Therapeutics by 11.8% in the fourth quarter. ProShare Advisors LLC now owns 42,006 shares of the biopharmaceutical company’s stock valued at $1,797,000 after buying an additional 4,442 shares during the period. Finally, New York State Common Retirement Fund raised its stake in shares of Acorda Therapeutics by 1.1% in the fourth quarter. New York State Common Retirement Fund now owns 149,231 shares of the biopharmaceutical company’s stock valued at $6,384,000 after buying an additional 1,565 shares during the period.

Acorda Therapeutics, Inc is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Company’s markets three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10milligrams, a treatment to improve walking in patients with multiple sclerosis (MS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.